Payment overview · 2025
General Payments
$584.07
23 reported records · 10 companies
Healthcare provider profile · identity verified
Havishakrishna Sarma, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PORTAGE, IN · NPI 1992934020
Verified facts
What the public records show
CMS Open Payments records show Havishakrishna Sarma, DO received $584.07 in general payments during 2025 across 23 reported records.
Vanda Pharmaceuticals Inc. accounted for 38.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Nurtec Odt, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $226.43 | 38.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $118.42 | 20.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.26 | 9.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.47 | 9.5% | 3 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $37.21 | 6.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.12 | 4.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.64 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.13 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.93 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $543.63 | 21 |
| Education | $40.44 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $226.43 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $75.90 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.47 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $46.64 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $28.20 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 42 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
318 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 504 | 103 |
| Eliquis | Apixaban | 318 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 52 |
| Sertraline Hcl | Sertraline Hcl | 287 | 34 |
| Donepezil Hcl | Donepezil Hcl | 282 | 40 |
| Gabapentin | Gabapentin | 278 | 50 |
| Alprazolam | Alprazolam | 268 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 248 | 73 |
| Metformin Hcl | Metformin Hcl | 247 | 25 |
| Memantine Hcl | Memantine Hcl | 227 | 30 |
| Furosemide | Furosemide | 218 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 196 | 59 |
| Carvedilol | Carvedilol | 191 | 44 |
| Montelukast Sodium | Montelukast Sodium | 191 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 41 |
| Omeprazole | Omeprazole | 183 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 59 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 172 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 28 |
| Losartan Potassium | Losartan Potassium | 161 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 40 |
| Jardiance | Empagliflozin | 140 | 34 |
| Potassium Chloride | Potassium Chloride | 135 | 39 |
| Famotidine | Famotidine | 114 | 18 |
| Mirtazapine | Mirtazapine | 114 | 21 |
| Xarelto | Rivaroxaban | 113 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 24 |
| Lisinopril | Lisinopril | 104 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 19 |
| Tramadol Hcl | Tramadol Hcl | 82 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 77 | 15 |
| Ozempic | Semaglutide | 77 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 76 | 26 |
| Trazodone Hcl | Trazodone Hcl | 76 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 22 |
| Buspirone Hcl | Buspirone Hcl | 70 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 14 |
| Aripiprazole | Aripiprazole | 60 | suppressed |
| Levetiracetam | Levetiracetam | 60 | 12 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 11 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 53 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 21 |
| Prednisone | Prednisone | 51 | 18 |
| Baclofen | Baclofen | 50 | suppressed |
| Levofloxacin | Levofloxacin | 49 | 19 |
| Mounjaro | Tirzepatide | 47 | 12 |
| Allopurinol | Allopurinol | 45 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 12 |
| Linzess | Linaclotide | 42 | 14 |
| Risperidone | Risperidone | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 16 |
| Azithromycin | Azithromycin | 38 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 12 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Cephalexin | Cephalexin | 35 | 25 |
| Lubiprostone | Lubiprostone | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 26 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Glucagon Emergency Kit | Glucagon | 32 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Meloxicam | Meloxicam | 31 | 14 |
| Simvastatin | Simvastatin | 31 | 12 |
| Xifaxan | Rifaximin | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 22 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | 11 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 11 |
| Lactulose | Lactulose | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Ertapenem | Ertapenem Sodium | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 11 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Latanoprost | Latanoprost | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Fetzima | Levomilnacipran Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Torsemide | Torsemide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $584.07 · 23 records | Vanda Pharmaceuticals Inc. | AIRSUPRA, AVYCAZ, DALVANCE, EMBLAVEO, FANAPT, KRYSTEXXA, Kerendia, LINZESS, NURTEC ODT, REXULTI, UBRELVY, ZAVZPRET, ZEPBOUND, Zubsolv | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error